Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.51
SNY's Cash to Debt is ranked lower than
74% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. SNY: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
SNY' s 10-Year Cash to Debt Range
Min: 0.14  Med: 0.57 Max: 10.62
Current: 0.51
0.14
10.62
Equity to Asset 0.58
SNY's Equity to Asset is ranked lower than
56% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. SNY: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
SNY' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.58 Max: 0.65
Current: 0.58
0.48
0.65
Interest Coverage 10.15
SNY's Interest Coverage is ranked lower than
79% of the 370 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 933.44 vs. SNY: 10.15 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s 10-Year Interest Coverage Range
Min: 8.34  Med: 12.12 Max: 19.65
Current: 10.15
8.34
19.65
F-Score: 6
Z-Score: 2.48
M-Score: -2.38
WACC vs ROIC
9.33%
15.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.44
SNY's Operating margin (%) is ranked higher than
79% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. SNY: 17.44 )
Ranked among companies with meaningful Operating margin (%) only.
SNY' s 10-Year Operating margin (%) Range
Min: 15.25  Med: 18.52 Max: 38.21
Current: 17.44
15.25
38.21
Net-margin (%) 12.34
SNY's Net-margin (%) is ranked higher than
73% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. SNY: 12.34 )
Ranked among companies with meaningful Net-margin (%) only.
SNY' s 10-Year Net-margin (%) Range
Min: 7.92  Med: 15.03 Max: 25.8
Current: 12.34
7.92
25.8
ROE (%) 15.78
SNY's ROE (%) is ranked higher than
76% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.87 vs. SNY: 15.78 )
Ranked among companies with meaningful ROE (%) only.
SNY' s 10-Year ROE (%) Range
Min: 5.18  Med: 10.42 Max: 33.55
Current: 15.78
5.18
33.55
ROA (%) 9.14
SNY's ROA (%) is ranked higher than
75% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. SNY: 9.14 )
Ranked among companies with meaningful ROA (%) only.
SNY' s 10-Year ROA (%) Range
Min: 2.62  Med: 6.14 Max: 21.59
Current: 9.14
2.62
21.59
ROC (Joel Greenblatt) (%) 79.01
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.80 vs. SNY: 79.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.95  Med: 49.01 Max: 145.55
Current: 79.01
31.95
145.55
Revenue Growth (3Y)(%) -1.00
SNY's Revenue Growth (3Y)(%) is ranked lower than
70% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. SNY: -1.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1  Med: 6.30 Max: 27.4
Current: -1
-1
27.4
EBITDA Growth (3Y)(%) -4.10
SNY's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 476 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. SNY: -4.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.1  Med: 5.70 Max: 35.7
Current: -4.1
-4.1
35.7
EPS Growth (3Y)(%) -8.20
SNY's EPS Growth (3Y)(%) is ranked lower than
66% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. SNY: -8.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -12.8  Med: 3.40 Max: 41.2
Current: -8.2
-12.8
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.30%)
Ken Fisher 13,079,575 sh (+1.18%)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
Murray Stahl 26,000 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
First Eagle Investment 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
First Eagle Investment 34,157 sh (-94.39%)
» More
Q4 2014

SNY Guru Trades in Q4 2014

David Dreman 1,102 sh (New)
Steven Cohen 1,050,000 sh (New)
NWQ Managers 2,941,923 sh (+22.12%)
HOTCHKIS & WILEY 11,692,693 sh (+18.16%)
Charles Brandes 2,571,795 sh (+14.36%)
Mario Gabelli 5,195 sh (+13.43%)
PRIMECAP Management 4,287,207 sh (+10.17%)
James Barrow 30,804,459 sh (+8.87%)
John Buckingham 22,394 sh (+8.37%)
Manning & Napier Advisors, Inc 5,433,472 sh (+8.13%)
Murray Stahl 26,295 sh (+1.13%)
Dodge & Cox 43,272,800 sh (+0.01%)
Bill Nygren 5,670,000 sh (unchged)
First Eagle Investment 34,157 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Ken Fisher 13,085,033 sh (-0.46%)
Scott Black 176,460 sh (-1.09%)
Third Avenue Management 10,704 sh (-13.02%)
Sarah Ketterer 506,796 sh (-14.67%)
» More
Q1 2015

SNY Guru Trades in Q1 2015

Paul Tudor Jones 7,598 sh (New)
NWQ Managers 3,927,517 sh (+33.50%)
John Buckingham 24,608 sh (+9.89%)
HOTCHKIS & WILEY 11,782,180 sh (+0.77%)
Charles Brandes 2,573,969 sh (+0.08%)
Warren Buffett 3,905,875 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
David Dreman 1,102 sh (unchged)
Francis Chou 410,000 sh (unchged)
Steven Cohen Sold Out
First Eagle Investment Sold Out
Third Avenue Management Sold Out
Ken Fisher 13,058,095 sh (-0.21%)
Murray Stahl 26,185 sh (-0.42%)
Scott Black 175,625 sh (-0.47%)
Dodge & Cox 43,034,073 sh (-0.55%)
James Barrow 30,225,221 sh (-1.88%)
Sarah Ketterer 477,367 sh (-5.81%)
PRIMECAP Management 3,972,907 sh (-7.33%)
Mario Gabelli 4,700 sh (-9.53%)
Manning & Napier Advisors, Inc 2,499,440 sh (-54.00%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 27.22
SNY's P/E(ttm) is ranked higher than
60% of the 469 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.80 vs. SNY: 27.22 )
Ranked among companies with meaningful P/E(ttm) only.
SNY' s 10-Year P/E(ttm) Range
Min: 9.64  Med: 19.91 Max: 38.97
Current: 27.22
9.64
38.97
Forward P/E 7.73
SNY's Forward P/E is ranked higher than
68% of the 244 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. SNY: 7.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.30
SNY's PE(NRI) is ranked higher than
60% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.50 vs. SNY: 28.30 )
Ranked among companies with meaningful PE(NRI) only.
SNY' s 10-Year PE(NRI) Range
Min: 9.82  Med: 19.89 Max: 39.2
Current: 28.3
9.82
39.2
P/B 2.08
SNY's P/B is ranked higher than
69% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. SNY: 2.08 )
Ranked among companies with meaningful P/B only.
SNY' s 10-Year P/B Range
Min: 1.11  Med: 1.73 Max: 2.38
Current: 2.08
1.11
2.38
P/S 3.46
SNY's P/S is ranked lower than
51% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. SNY: 3.46 )
Ranked among companies with meaningful P/S only.
SNY' s 10-Year P/S Range
Min: 1.77  Med: 2.84 Max: 5.18
Current: 3.46
1.77
5.18
PFCF 63.24
SNY's PFCF is ranked lower than
64% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.65 vs. SNY: 63.24 )
Ranked among companies with meaningful PFCF only.
SNY' s 10-Year PFCF Range
Min: 16.82  Med: 28.82 Max: 82.54
Current: 63.24
16.82
82.54
POCF 47.44
SNY's POCF is ranked lower than
67% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.21 vs. SNY: 47.44 )
Ranked among companies with meaningful POCF only.
SNY' s 10-Year POCF Range
Min: 13.84  Med: 27.38 Max: 64.69
Current: 47.44
13.84
64.69
EV-to-EBIT 20.40
SNY's EV-to-EBIT is ranked higher than
56% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.91 vs. SNY: 20.40 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s 10-Year EV-to-EBIT Range
Min: 10.5  Med: 20.80 Max: 204.2
Current: 20.4
10.5
204.2
Shiller P/E 23.10
SNY's Shiller P/E is ranked higher than
70% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.23 vs. SNY: 23.10 )
Ranked among companies with meaningful Shiller P/E only.
SNY' s 10-Year Shiller P/E Range
Min: 11.32  Med: 16.86 Max: 25.58
Current: 23.1
11.32
25.58
Current Ratio 1.80
SNY's Current Ratio is ranked lower than
62% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. SNY: 1.80 )
Ranked among companies with meaningful Current Ratio only.
SNY' s 10-Year Current Ratio Range
Min: 0.79  Med: 1.68 Max: 2.71
Current: 1.8
0.79
2.71
Quick Ratio 1.29
SNY's Quick Ratio is ranked lower than
64% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. SNY: 1.29 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s 10-Year Quick Ratio Range
Min: 0.59  Med: 1.26 Max: 2.41
Current: 1.29
0.59
2.41
Days Inventory 156.14
SNY's Days Inventory is ranked lower than
70% of the 616 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.37 vs. SNY: 156.14 )
Ranked among companies with meaningful Days Inventory only.
SNY' s 10-Year Days Inventory Range
Min: 155.87  Med: 189.97 Max: 224.59
Current: 156.14
155.87
224.59
Days Sales Outstanding 74.40
SNY's Days Sales Outstanding is ranked lower than
51% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.51 vs. SNY: 74.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s 10-Year Days Sales Outstanding Range
Min: 61.29  Med: 74.50 Max: 103.32
Current: 74.4
61.29
103.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.24
SNY's Dividend Yield is ranked higher than
89% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. SNY: 3.24 )
Ranked among companies with meaningful Dividend Yield only.
SNY' s 10-Year Dividend Yield Range
Min: 1.41  Med: 3.68 Max: 5.46
Current: 3.24
1.41
5.46
Dividend Payout 0.84
SNY's Dividend Payout is ranked lower than
86% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. SNY: 0.84 )
Ranked among companies with meaningful Dividend Payout only.
SNY' s 10-Year Dividend Payout Range
Min: 0.27  Med: 0.59 Max: 1
Current: 0.84
0.27
1
Dividend growth (3y) 3.80
SNY's Dividend growth (3y) is ranked lower than
60% of the 246 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. SNY: 3.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
SNY' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 6.50 Max: 29.6
Current: 3.8
0
29.6
Yield on cost (5-Year) 4.14
SNY's Yield on cost (5-Year) is ranked higher than
88% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. SNY: 4.14 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.8  Med: 4.70 Max: 6.97
Current: 4.14
1.8
6.97
Share Buyback Rate -0.10
SNY's Share Buyback Rate is ranked higher than
76% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.40 vs. SNY: -0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3  Med: -0.40 Max: -24.6
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 44.83
SNY's Price/Tangible Book is ranked lower than
98% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. SNY: 44.83 )
Ranked among companies with meaningful Price/Tangible Book only.
SNY' s 10-Year Price/Tangible Book Range
Min: 7.22  Med: 13.30 Max: 42.03
Current: 44.83
7.22
42.03
Price/Projected FCF 0.77
SNY's Price/Projected FCF is ranked higher than
68% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. SNY: 0.77 )
Ranked among companies with meaningful Price/Projected FCF only.
SNY' s 10-Year Price/Projected FCF Range
Min: 0.92  Med: 1.22 Max: 1.71
Current: 0.77
0.92
1.71
Price/Median PS Value 1.02
SNY's Price/Median PS Value is ranked higher than
55% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. SNY: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
SNY' s 10-Year Price/Median PS Value Range
Min: 0.69  Med: 1.05 Max: 2.66
Current: 1.02
0.69
2.66
Price/Graham Number 6.85
SNY's Price/Graham Number is ranked lower than
88% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.75 vs. SNY: 6.85 )
Ranked among companies with meaningful Price/Graham Number only.
SNY' s 10-Year Price/Graham Number Range
Min: 1.94  Med: 4.61 Max: 6.42
Current: 6.85
1.94
6.42
Earnings Yield (Greenblatt) (%) 5.08
SNY's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. SNY: 5.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 4.80 Max: 9.5
Current: 5.08
0.5
9.5
Forward Rate of Return (Yacktman) (%) -2.99
SNY's Forward Rate of Return (Yacktman) (%) is ranked lower than
70% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. SNY: -2.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -3.3  Med: 20.00 Max: 48.5
Current: -2.99
-3.3
48.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW.Germany, SNYN.Mexico, SAN.Switzerland, SANNV.France, SNYNF.USA, SNW2.Germany,
Sanofi was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
Mt Stocks Apr 19 2015 
Scottrade Mar 22 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 

More From Other Websites
Sanofi Signs a Global Agreement with SUEZ environnement To Enhance Water and Waste Management Jul 02 2015
What Is Beyond Vision-Loss Blockbuster For Regeneron? Jul 01 2015
Analysts Battle Over MannKind -- but Who's Right? Jul 01 2015
The Zacks Analyst Blog Highlights: Delhaize Group, Sanofi and Luxfer Holdings - Press Releases Jul 01 2015
MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin Jun 30 2015
Roche 'High Efficacy' MS Drug Succeeds In Trials Jun 30 2015
Is Grexit Inevitable? 3 Stocks to Buy - Analyst Blog Jun 30 2015
New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol Jun 30 2015
New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol Jun 30 2015
3 European Stocks Paying Juicy Dividends Jun 29 2015
New Sanofi CEO to unveil five-year plan in November - unions Jun 26 2015
New Sanofi CEO to unveil five-year plan in November -unions Jun 26 2015
Pep Boys, Acacia Research, Sanofi, Unilever and Continental Aktiengesellschaft highlighted as Zacks... Jun 24 2015
Viehbacher to head $2bn Bertarelli healthcare fund Jun 23 2015
Greece Deal Likely? 3 Stock Picks - Analyst Blog Jun 23 2015
Former Sanofi CEO Makes Science Comeback With Bertarelli Fund Jun 23 2015
Top Europe Stocks Rally On Greece Bailout Hopes Jun 22 2015
Biotechs about to break out: Pro Jun 19 2015
Sanofi Starts Dosing in Phase I/II Study on Olipudase Alfa - Analyst Blog Jun 16 2015
We've Only Seen This Contrarian Buy Signal One Other Time Since 2009 Jun 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK